Oral Session 2-9B CML: Clinical trials

[OS2-9B-2] Impact of tyrosine kinase inhibitor on adult height in chronic-phase CML children

Haruko Shima¹, Akihiko Tanizawa¹, Hidemitsu Kurosawa¹, Akihiro Watanabe¹, Masaki Ito¹, Chikako Tono¹, Yuki Yuza¹, Hideki Muramatsu¹, Kazuko Hamamoto¹, Masahiko Okada¹, Koji Kato², Kimikazu Matsumoto³, Norio Shiba⁴, Hiroyuki Shimada¹ (1.JCCG, CML committee, 2.Pediatric Hematology/Oncology, Japanese Red Cross Nagoya First Hospital, Aichi, Japan, 3.Children's Cancer Center, NCCHD, Tokyo, Japan, 4.Dept. Pediatrics, Yokohama City University Hospital, Kanagawa, Japan)